Vol 5, No 4 (2016)
Review article
Published online: 2016-11-03
Metformin — today’s panacea?
DOI: 10.5603/DK.2016.0020
Clin Diabetol 2016;5(4):117-122.
Abstract
Metformin is still an immutable basic hypoglycemic drug used in pharmacotherapy of diabetes mellitus type 2. Structurally it belongs to biguanide derivatives that was discovered in traditional herbalism. Galega officinalis was a plant used to obtain substances similar to metformin. This drug can induce a state in a cell, which occurs as a result of caloric restriction. It consists in decreasing the effectiveness of IGF-1 metabolic pathway with the insulin-like growth factor 1 and mTOR kinase activity, thus metformin contributes to extend a lifespan among animals. This article presents a brief overview of studies about anti-aging potential of metformin. Beside this, the authors have described caloric restriction role taking part in a lifespan as well as slowing down incidence of age related diseases.
Keywords: metforminagingmTOR kinaseIGF-1 pathwaystudies
References
- Dudkiewicz M. Kucharewicz. Związki pochodzenia naturalnego modulujące starzenie i śmierć komórek. Postępy Biochemii. 2014; 60: 207–220.
- Doustne leki przeciwcukrzycowe i agoniści receptora GLP-1 w terapii cukrzycy typu 2. . In: Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2016. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabet Klin 2016: A16–A18.
- Werner E, Bell J. CCXIV.—The preparation of methylguanidine, and of ββ-dimethylguanidine by the interaction of dicyanodiamide, and methylammonium and dimethylammonium chlorides respectively. J. Chem. Soc., Trans. 1922; 121(0): 1790–1794.
- STERNE J. [Treatment of diabetes mellitus with N,N-dimethylguanylguanidine (LA. 6023, glucophage)]. Therapie. 1959; 14: 625–630.
- Strojek K, Wróbel M, Szymborska-Kajanek A, et al. Metformina — nowe wskazania refundacyjne. Diabet Klin. 2013; 2: 120–124.
- Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32(9): 1620–1625.
- Colman RJ, Beasley TM, Kemnitz JW, et al. Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys. Nat Commun. 2014; 5: 3557.
- McCay CM, Crowell MF, Maynard LA. The effect of retarded growth upon the length of life span and upon the ultimate body size. 1935. Nutrition. 1989; 5(3): 155–172.
- Sikora E. Starzenie i długowieczność. Postępy Biochemii. 2014; 60: 125–137.
- Brown-Borg HM, Bode AM, Bartke A. Antioxidative mechanisms and plasma growth hormone levels: potential relationship in the aging process. Endocrine. 1999; 11(1): 41–48.
- Lund J, Tedesco P, Duke K, et al. Transcriptional profile of aging in C. elegans. Curr Biol. 2002; 12(18): 1566–1573.
- Flachsbart F, Caliebe A, Kleindorp R, et al. Association of FOXO3A variation with human longevity confirmed in German centenarians. Proc Natl Acad Sci U S A. 2009; 106(8): 2700–2705.
- Suh Y, Atzmon G, Cho MO, et al. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci U S A. 2008; 105(9): 3438–3442.
- Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007; 12(1): 9–22.
- Karczmarek-Borowska B, Zmorzyński S, Filip A. Biologczna rola surwiwiny. Współ Onkol. 2008; 12: 437–440.
- Vaira V, Lee CW, Goel HL, et al. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene. 2007; 26(19): 2678–2684.
- Selvarajah J, Elia A, Carroll VA, et al. DNA damage-induced S and G2/M cell cycle arrest requires mTORC2-dependent regulation of Chk1. Oncotarget. 2015; 6(1): 427–440.
- Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013; 493(7432): 338–345.
- Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009; 460(7253): 392–395.
- Roth GS, Lane MA, Ingram DK, et al. Biomarkers of caloric restriction may predict longevity in humans. Science. 2002; 297(5582): 811.
- van Heemst D, Beekman M, Mooijaart SP, et al. Reduced insulin/IGF-1 signalling and human longevity. Aging Cell. 2005; 4(2): 79–85.
- Holloszy JO, Fontana L. Caloric restriction in humans. Exp Gerontol. 2007; 42(8): 709–712.
- Meyer TE, Kovács SJ, Ehsani AA, et al. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J Am Coll Cardiol. 2006; 47(2): 398–402.
- Fontana L, Meyer TE, Klein S, et al. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci U S A. 2004; 101(17): 6659–6663.
- Willcox DC, Willcox BJ, Todoriki H, et al. Caloric restriction and human longevity: what can we learn from the Okinawans? Biogerontology. 2006; 7(3): 173–177.
- Ingram DK, Zhu M, Mamczarz J, et al. Calorie restriction mimetics: an emerging research field. Aging Cell. 2006; 5(2): 97–108.
- Longo VD, Finch CE. Evolutionary medicine: from dwarf model systems to healthy centenarians? Science. 2003; 299(5611): 1342–1346.
- Anisimov VN. Metformin: do we finally have an anti-aging drug? Cell Cycle. 2013; 12(22): 3483–3489.
- Anisimov VN, Bartke A. The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol. 2013; 87(3): 201–223.
- Mattison JA, Roth GS, Beasley TM, et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature. 2012; 489(7415): 318–321.
- Anisimov VN. Carcinogenesis and aging 20 years after: escaping horizon. Mech Ageing Dev. 2009; 130(1-2): 105–121.
- Dilman VM. Age-associated elevation of hypothalamic, threshold to feedback control, and its role in development, ageine, and disease. Lancet. 1971; 1(7711): 1211–1219.
- Anisimov VN, Berstein LM, Egormin PA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol. 2005; 40(8-9): 685–693.
- Anisimov VN, Egormin PA, Piskunova TS, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle. 2010; 9(1): 188–197.
- Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008; 7(17): 2769–2773.
- Anisimov VN, Piskunova TS, Popovich IG, et al. Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. Aging (Albany NY). 2010; 2(12): 945–958.
- Anisimov VN, Berstein LM, Popovich IG, et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY). 2011; 3(2): 148–157.
- Anisimov VN, Popovich IG, Zabezhinski MA, et al. Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin. Cell Cycle. 2015; 14(1): 46–55.
- Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun. 2013; 4: 2192.
- Onken B, Driscoll M. Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS One. 2010; 5(1): e8758.
- Bannister CA, Holden SE, Jenkins-Jones S, et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab. 2014; 16(11): 1165–1173.
- Taubes G. Cancer research. Cancer prevention with a diabetes pill? Science. 2012; 335(6064): 29.
- Check Hayden E. Anti-ageing pill pushed as bona fide drug. Nature. 2015; 522(7556): 265–266.
- Hall SS. A Trial for the ages. Science. 2015; 349(6254): 1274–1278.
- Taubes G. Cancer research. Cancer prevention with a diabetes pill? Science. 2012; 335(6064): 29.